Emcure Pharma Share Price Drop Nearly 5 Percent As Block Deal Overhang Weighs

Mumbai, November 18, 2025: There was a fall in the shares of Emcure Pharmaceuticals Limited in the early morning trade on Tuesday. The stock started the day weaker than the earlier close of ₹1394.10 at ₹1341 and soon slipped down by close to 5% within the first hour of trading (at ₹1326 per share). At 10:10 AM, there was a bit of consolidation as the price was ₹1345.50 (3.49% lower than the previous day’s close.

The top reason for the fall in the stock’s price is due to the block deal on the exchanges today, worth approximately 2.4% of the company’s equity (5.17 million shares were traded on BSE and 1.63 million on the NSE).

Trigger for the Price Movement

As per media reports, BC Investment IV (an affiliate of global private equity firm Bain Capital), which currently holds 6.3% in the company, was looking to offload 2% of its holding (for an estimated value of ₹493 crore). The floor price proposed for the deal is ₹1296.50. The possibility of this deal will mean a large supply of the company’s shares, creating a near-term overhang.

In addition to this, there was a critical surge of 25% in PAT of the company along with a 13.30% increase in the revenue from operations, as reported in the Q2 FY26 results, causing a surge of almost 5% a day ago.

Management Outlook

As the company continued its strong financial performance, the management expressed hope of entering into new markets through Novo Nordisk partnerships in the obesity segment. As the sector is undergoing tremendous change, it will be an excellent time to have a first-mover advantage.

Emcure Pharmaceuticals Ltd is a listed Indian pharmaceutical company engaged in developing, manufacturing and marketing a wide range of pharmaceutical products across global markets. It is part of the Nifty Smallcap 250 index and has been listed since July 2024.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations